New Key Statistics Module, Z-Score and F-Score
NAS:CLDX Key Ratios
| Market Cap $ M | 2,767.51 |
| Enterprise Value $ M | 1,960.28 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 3.40 |
| Price/Sales | 274.68 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 8.00 |
| EPS (TTM) $ | -2.75 |
| Beneish M-Score | 2.38 |
| 10-y EBITDA Growth Rate % | 24.40 |
| 5-y EBITDA Growth Rate % | 15.10 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -12.00 |
| EV-to-EBITDA | -12.24 |
| PEG | -- |
| Shares Outstanding M | 66.29 |
| Net Margin (%) | -1,809.40 |
| Operating Margin % | -1,966.89 |
| Pre-tax Margin (%) | -1,809.40 |
| Quick Ratio | 29.36 |
| Current Ratio | 29.36 |
| ROA % (ttm) | -27.22 |
| ROE % (ttm) | -28.82 |
| ROIC % (ttm) | -419.65 |
| Dividend Yield % | -- |
| Altman Z-Score | 49.98 |
CLDX Number of Guru Trades
CLDX Volume of Guru Trades
Gurus Latest Trades with NAS:CLDX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:CLDX is held by these investors
Total 2
Celldex Therapeutics Inc Insider Transactions
No Available Data
News about NAS:CLDX
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers